An interventional study of Exercise and Essential Amino Acids in Heart Failure, Diastolic, sponsored by Arizona State University. Terminated at 2 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2019-09-03.
Sponsored by Arizona State University · Not applicable, Interventional, and Other
Half of heart failure patients have preserved ejection fraction (HFpEF). Like patients with reduced ejection fraction (HFrEF), HFpEF patients suffer from exercise intolerance (low VO2max), which reduces physical function, quality of life, and survival. Strikingly, there is no medication proven to increase survival for HFpEF patients. Whereas exercise intolerance in HFrEF patients is the result of cardiovascular limitations, physical dysfunction in HFpEF patients is largely the result of peripheral abnormalities in skeletal muscle. Indeed, research in HFpEF patients identified that physical function and VO2peak are directly related to leg lean mass, and drugs focused on improving cardiovascular function have failed to improve VO2peak. Unfortunately, no therapy has been identified for this population that can concurrently improve cardiovascular and muscle health. The need for improved muscle therapies is reinforced by the fact that HFpEF patients are commonly older adults who are predisposed to muscle wasting. Strategic essential amino acid (EAA) ingestion has been shown to improve the adaptive response of muscle to exercise. Therefore, the investigators will determine, in HFpEF patients, the extent to which ingesting a strategic mixture of EAAs during an acute aerobic exercise training program enhances the response to this exercise strategy.
Exclusion Criteria:
Participants will be provided with essential amino acids during exercise training.
Other: Exercise · Dietary Supplement: Essential Amino Acids
Participants will be provided with placebo supplement during exercise training.
Other: Exercise · Dietary Supplement: Placebo
Aerobic exercise performed 3/d per week during intervention
Mixture of 10g of essential amino acids ingested throughout intervention
10g of maltodextrin ingested throughout intervention
Change in VO2max
Change in maximal Aerobic Capacity
Time frame: Change from pre to after the 4 week intervention
Change in Flow-mediated Dilation
Change in blood vessel function
Time frame: Change from pre to after the 4 week intervention
Change in Pulse wave velocity
Change in pulse wave velocity
Time frame: Change from pre to after the 4 week intervention
Change in Diastolic Function
Change in diastolic Function
Time frame: Change from pre to after the 4 week intervention
Change in Skeletal Muscle mRNA expression
Change in skeletal Muscle mRNA expression
Time frame: Change from pre to after the 4 week intervention
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arizona State University